Barclays initiated coverage on Viatris with a new price target
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2026 | $18.00 | Neutral → Buy | UBS |
| 1/16/2026 | $15.00 | Hold → Buy | Argus |
| 12/9/2025 | $15.00 | Overweight | Barclays |
| 10/15/2025 | $15.00 | Buy | Truist |
| 6/6/2025 | $10.00 | Neutral | Goldman |
| 7/19/2024 | $15.00 | Buy | Jefferies |
| 10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
| 6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
8-K - Viatris Inc (0001792044) (Filer)
SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)
8-K - Viatris Inc (0001792044) (Filer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00
Argus upgraded Viatris from Hold to Buy and set a new price target of $15.00
Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00
Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key Metrics[1]Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026Provides 2026 Financial Guidance; Positioned for Sustainable GrowthAnticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline MilestonesCompletes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 YearsPITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced robust financial results for the four
PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026. This marks the sixth consecutive year the Company has paid a dividend. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of bo
FDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026. Presbyopia is the age-related progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain. The condition affects approximately 90% of adults in the U.S. over the age of 45."FDA's acceptance of this supplemental New Drug Applicati
3 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key Metrics[1]Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026Provides 2026 Financial Guidance; Positioned for Sustainable GrowthAnticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline MilestonesCompletes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 YearsPITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced robust financial results for the four
PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026. This marks the sixth consecutive year the Company has paid a dividend. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of bo
PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. In addition, Viatris will host an Investor Event on March 19, 2026, in New York City. More details regarding the event will be provided during the Co
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)
Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition
PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies. Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional
PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.